J
Jesús Cobo
Researcher at Autonomous University of Barcelona
Publications - 52
Citations - 1315
Jesús Cobo is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Schizophrenia & Positive and Negative Syndrome Scale. The author has an hindex of 14, co-authored 51 publications receiving 970 citations. Previous affiliations of Jesús Cobo include Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review
TL;DR: Overall, gender differences have been found in a number of variables, and further study in this area could help provide useful information with a view to improving the care of these patients.
Journal ArticleDOI
Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial
Elena Huerta-Ramos,Raquel Iniesta,Susana Ochoa,Jesús Cobo,Eva Miquel,Mercedes Roca,Antoni Serrano-Blanco,Fernando Teba,Judith Usall +8 more
TL;DR: The use of raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia seems to be useful in improving cognitive symptoms, and significant differences in some aspects of memory and executive function are found.
Journal ArticleDOI
Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
Laura Morata,Jesús Cobo,Marta Fernandez-Sampedro,P Guisado Vasco,E Ruano,Jaime Lora-Tamayo,M Sánchez Somolinos,P González Ruano,A Rico Nieto,Ainara Arnaiz,M Estébanez Muñoz,Manuel E. Jiménez-Mejías,A B Lozano Serrano,Elena Múñez,Dolors Rodríguez-Pardo,R Argelich,Ángel Arroyo,José Maria Barbero,F Cuadra,A. del Arco,M.D. del Toro,L Guio,D Jimenez-Beatty,N Lois,O. Martin,R M Martínez Alvarez,F J Martinez-Marcos,L Porras,Maria Soledad Ramirez,J Vergas García,A. Soriano +30 more
TL;DR: The results show that dalbavancin is a well-tolerated antibiotic, even when >2 doses are administered, and is associated with a high cure rate.
Journal ArticleDOI
Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial
Judith Usall,Elena Huerta-Ramos,Javier Labad,Jesús Cobo,Christian Núñez,Marta Creus,Gemma García Parés,Daniel Cuadras,José Franco,Eva Miquel,Julio César Reyes,Mercedes Roca +11 more
TL;DR: In conclusion, raloxifene improved negative and general psychopathological symptoms, compared with antipsychotic medication alone, in postmenopausal women with schizophrenia.
Journal ArticleDOI
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis
Virginia Soria,Alexandre González-Rodríguez,Elena Huerta-Ramos,Judith Usall,Jesús Cobo,Miquel Bioque,Juan David Barbero,Clemente Garcia-Rizo,Meritxell Tost,José Antonio Monreal,Javier Labad,Javier Labad +11 more
TL;DR: The use of drugs targeting hormones related to the HPA axis and sex steroids is a promising field of research that might help to improve the cognitive outcome of patients with schizophrenia, bipolar disorder and major depressive disorder in the near future.